NCT05241249View on ClinicalTrials.gov

Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

February 1, 2022

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Pancreas Cancer
Interventions
DRUG

Bethanechol

Study Drug: Bethanechol (generic), supplied as 50mg oral tablets. Subjects will take 2 tablets (100mg) twice daily. Medication should be taken 1 hour before meals in AM and PM. Medication will be purchased commercially and dispensed at the research pharmacy.

DRUG

Gemcitabine

Non-experimental. Chemotherapy will be administered on a day 1, 8 and 15 schedule with gemcitabine at a dose of 1000 mg/m2

DRUG

nab-paclitaxel

Non-experimental. Chemotherapy will be administered on a day 1, 8 and 15 schedule with nab-paclitaxel dose at 125 mg/m2

Trial Locations (1)

10032

RECRUITING

Columbia University Medical Center, New York

All Listed Sponsors
lead

Susan E. Bates

OTHER